| Biomarker ID | 95 |
| PMID | 15870707 |
| Year | 2005 |
| Biomarker | E-cadherin |
| Biomarker Basis | Concentration Based (μg/L) |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Humans |
| Regulation | Upregulated in Metastatic PCa: (Localised PCa: 9.46; Metastatic PCa: 27.49) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways include: 1. Integrin cell surface interactions 2. Nuclear beta-catenin signaling and target gene transcription regulation 3. Cell junction organization 4. Adherens junction cell adhesion 5. Neural crest differentiation |
| Experiment | Localised PCa Vs Metastatic PCa |
| Type of Biomarker | Prognostic |
| Cohort | First group consisted of 13 healthy people. The second group had 29 patients with benign prostatic hyperplasia (BPH). The third group consisted of 109 patients with localised prostate cancer (Loc PCA). None of these patients failed during follow-up after radical prostatectomy. The fourth group consisted of 21 cases with localised PCA and biochemical failure after surgery during follow-up. The last group consisted of 16 serum samples of patients with generalised metastatic disease.(Met PCA) |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.001 |
| Method Used | Enzyme Immunoassay (EIA) |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | CDH1 |